Milrinone (Lactate)

Milrinone (Lactate) is a phosphodiesterase III inhibitor similar to amrinone, with +ve ionotropic and vasodilator activity. It potentiate effects of cyclic adenosine monophosphate(cAMP). Milrinone (Lactate) is administered intravenosly in the management of heart failure(severe) unresponsive to other form & in acute heart failure after cardiac surgery.

Brands
MILRON
Adult Dose
Neonatal
Paedriatic
Dose: 50 to 75 mcg/kg
Single Dose: 62 (62.5)
Frequency: As recommended.
Route: IV
Instructions: Initial dose over dose over 30-60 min
Characteristics
Milrinone (Lactate) also known as Milrinona. . It is of Synthetic origin and belongs to Bipyridine. . The Molecular Weight of Milrinone (Lactate) is 301.30. It is strongly acidic drug and Its pKa is 4.5, 8.5, 8.6.
Contraindications
Milrinone (Lactate) is contraindicated in conditions like Allergy,Hypotension,Ventricular arrhythmias,Hypersensitivity,Pregnancy,Supraventricular arrhythmias,Prophylaxis of mycobacterium avium complex infections.
Effects
The severe or irreversible adverse effects of Milrinone (Lactate), which give rise to further complications include Hypotension, Bronchospasm, Hypotension, Bronchospasm, Angina, Anaphylaxis, Supraventricular arrhythmia, Ventricular arrhythmia.Milrinone (Lactate) produces potentially life-threatening effects which include Arrhythmias, Hypotension. which are responsible for the discontinuation of Milrinone (Lactate) therapy.The symptomatic adverse reactions produced by Milrinone (Lactate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Palpitation, Rashes, Hypotension, Somnolence, Tremor, Thrombocytopenia, Hypokalemia, Angina.
Indications
'Milrinone (Lactate) is primarily indicated in conditions like Acute heart failure, Congestive heart failure, Heart failure, Short-term treatment of severe congestive heart failure, Tobacco amblyopia and leber''s optic atrophy.'
Interactions
Milrinone (Lactate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAnagrelideIt should not be diluted with NaCO3 injection.BumetanideDobutamine (HCl)Frusemide or FurosemideIsoproterenolRiociguatClinical experience with co-administration is limited These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Liver Function Test (LFT)
Risks
Drug should not be given to Paediatrics, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
IV Inj, IV Inf Store at room temperature.
Warnings
Blood pressure, heart rate, ECG, fluid and electrolyte balance should be monitored during therapy. It should be used with caution in patients with severe obstructive aortic or pulmonary valvular disease or with hypertrophic cardiomyopathy and in children and in patients with decreased renal function,hypokalemia,hypotension.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.